The salvage therapy in lung adenocarcinoma initially harbored susceptible EGFR mutation and acquired resistance occurred to the first-line gefitinib and second-line cytotoxic chemotherapy

BACKGROUND: Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) such as gefitinib can provide better efficacy and prolonged progression free survival (PFS) than cytotoxic chemotherapy for metastatic lung non-squamous cell carcinoma harboring susceptible EGFR mutations when used a...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Chih-Jen, Hung, Jen-Yu, Tsai, Ming-Ju, Wu, Kuan-Li, Liu, Ta-Chih, Chou, Shah-Hwa, Lee, Jui-Ying, Hsu, Jui-Sheng, Huang, Ming-Shyan, Chong, Inn-Wen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5424380/
https://www.ncbi.nlm.nih.gov/pubmed/28486985
http://dx.doi.org/10.1186/s40360-017-0130-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5424380/
https://www.ncbi.nlm.nih.gov/pubmed/28486985
http://dx.doi.org/10.1186/s40360-017-0130-0

Ejemplares similares